FindTrial
Sign In

Efficacy and safety of novel combination therapy for high-risk non-muscular invasive bladder cancer

A retrospective cohort study of efficacy and safety of combination therapy for high-risk non-muscular invasive bladder cancer

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200058555
Enrollment
Unknown
Registered
2022-04-10
Start date
2022-04-10
Completion date
Unknown
Last updated
2024-01-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bladder cancer

Interventions

Group 1:BCG+ Intra-arterial iliac chemotherapy (IAC) was received
Group 2:Intravesical infusion chemotherapy (IVC) and IAC combined therapy
Group 3:Standard BCG immunotherapy

Sponsors

First Affiliated Hospital of Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 100 Years

Inclusion criteria

Inclusion criteria: 1. In recent 5 years, she was diagnosed with non-muscular invasive bladder cancer in our hospital and received transurethral resection of bladder tumor (TURBT); 2. Postoperative pathology confirmed that the patients fit the EAU risk stratification high-risk patients, namely: (1) T1 tumor; (2) G3 tumor; (3) Carcinoma in situ (CIS); (4) Multiple, multiple recurrence TaG1G2/LG tumors with large tumor diameter (>3cm).

Exclusion criteria

Exclusion criteria: 1. Bladder cancer was diagnosed in the first layer of the group and had received treatment; 2. Loss of follow-up; 3. Multiple tumors; 4. Withdrawal from treatment due to adverse reactions.

Design outcomes

Primary

MeasureTime frame
recurrence-free survival;progression-free survival;—

Secondary

MeasureTime frame
recurrence rate;progression rate;—

Countries

China

Contacts

Public ContactChen Junxing
chenjunx@mail.sysu.edu.cn+86 13312892966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026